We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Plasma Biomarkers Predict Severity of Malaria Infection

By LabMedica International staff writers
Posted on 29 Sep 2010
Two biomarkers have been found suitable to assess the severity of malaria in travelers returning with the disease.

The diagnostic accuracy of plasma soluble Triggering Receptor Expressed on Myeloid cells 1 (TREM-1), neopterin and procalcitonin levels as biomarkers for severe Plasmodium falciparum disease was evaluated. Neopterin belongs to the chemical group known as pteridines and procalcitonin is a peptide precursor of the hormone calcitonin. Both substances are involved in the systemic proinflammatory response of the host to invading pathogens.

In a study carried at the Erasmus Medical Center (Rotterdam, the Netherlands), levels of the biomarkers for severe P. falciparum disease was evaluated in 104 travelers with imported malaria. Twenty-six patients had non-P. falciparum malaria, 64 patients were with uncomplicated P. falciparum malaria and 14 patients had severe P. falciparum malaria). The diagnostic performance of TREM-1, procalcitonin and neopterin for malaria disease severity was compared with that of plasma lactate, which is routinely measured in returning travelers who are ill.

Malaria was diagnosed by Quantitative Buffy Coat analysis, by a rapid diagnostic antigen test for malaria and by conventional microscopy of stained thick and thin blood smears. TREM-1 and neopterin levels were determined in serum samples using commercially available enzyme-linked immunoassay (ELISA) tests. Procalcitonin levels in serum samples were determined using a commercially available enzyme immunoassay test. Normal serum values are <100 pg/mL for TREM-1, <3 ng/mL for neopterin and < 0.1 ng/mL for procalcitonin.

Patients with severe P. falciparum malaria had significantly higher neopterin and procalcitonin levels on admission when compared to patients with uncomplicated P. falciparum malaria or non-P. falciparum malaria. No significant differences in TREM-1 levels were detected between the different patient groups. At a cut-off point of 10.0 ng/mL, neopterin had a positive and negative predictive value of 0.38 and 0.98, whereas procalcitonin, at a cut-off point of 0.9 ng/mL, had a positive and negative predictive value of 0.30 and 1.00. The study was published online in September 14, 2010, in the Malaria Journal.

Although the diagnostic value of neopterin and procalcitonin is limited, the high negative predictive value of both neopterin and procalcitonin may be helpful for a rapid exclusion of severe malaria disease on admission. This may be a valuable tool for physicians only occasionally dealing with returned travelers from malaria-endemic regions and who need to decide on subsequent oral antimalarial treatment or timely referral to a specialized center for high-level monitoring and intensified parenteral treatment.

Related Links:
Erasmus Medical Center



Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Toxoplasma Gondii Immunoassay
Toxo IgM AccuBind ELISA Kit
New
Auto Clinical Chemistry Analyzer
cobas c 703
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The experimental blood test accurately indicates severity and predicts potential recovery from spinal cord injury (Photo courtesy of 123RF)

Blood Test Identifies Multiple Biomarkers for Rapid Diagnosis of Spinal Cord Injury

The National Institutes of Health estimates that 18,000 individuals in the United States sustain spinal cord injuries (SCIs) annually, resulting in a staggering financial burden of over USD 9.... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more

Industry

view channel
Image: Tumor-associated macrophages visualized using the Multiomic LS Assay (Photo courtesy of ACD)

Leica Biosystems and Bio-Techne Expand Spatial Multiomic Collaboration

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD, Newark, CA, USA), and Leica Biosystems (Nussloch,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.